Since MSCs can migrate to the tumor site and ASC-IFN-β can locally express IFN-β and TRAIL at high concentrations, the clinical applicability of ASC-IFN-β is greater than that of IFN-β and TRAIL administration. Here, IFNB1 is linked to neoplasm.